Sign up
Quantellect · Congress · Trade Detail
CVETCovetrus, Inc. (CVET) [ST] F ILINg S TATuS : New S ubHOLdINg O F : Cindy Axne IRA
DemocratHouse

Cynthia Axne bought Covetrus, Inc. (CVET) [ST] F ILINg S TATuS : New S ubHOLdINg O F : Cindy Axne IRA (CVET)

Cynthia Axne (D-IA), a U.S. Representative, has disclosed 3 trades in Covetrus, Inc. (CVET) [ST] F ILINg S TATuS : New S ubHOLdINg O F : Cindy Axne IRA (CVET) since 2019, all purchases, worth an estimated $24K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).

The trade highlighted here is a purchase: Cynthia Axne bought $1,001 - $15,000 of Covetrus, Inc. (CVET) [ST] F ILINg S TATuS : New S ubHOLdINg O F : Cindy Axne IRA (CVET) on February 6, 2019. Since that trade, CVET is up +0.00% against the S&P 500 up +198.21%, an outperformance of -198.21%.

Across these filings, Cynthia Axne has been a net buyer of CVET. The most recent disclosed CVET transaction shown was dated February 8, 2019. Each row in the table below links to that trade and its post-trade performance versus the market.

Data updated

CVET trades
3
Disclosed Vol
$24K
Buys
3
100%
Sells
0
0%
Buy / Sell
All buys
ratio
First → Last
2019

Cynthia Axne's CVET trades vs the price

CVET is up +0.00% since Cynthia Axne bought on February 6, 2019, versus +198.21% for the S&P 500.

Performance since this trade

Price change since trade
+0.00%
S&P 500 change since trade
+198.21%
Outperformance vs S&P 500
-198.21%

All Cynthia Axne CVET trades

TradedTypeSizeReturnEst. profit
February 8, 2019BUY$1,001 - $15,000N/A
February 6, 2019BUY$1,001 - $15,000N/A
February 6, 2019BUY$1,001 - $15,000N/A

Estimated profit is shown for buys only, marked to the latest close. It is an estimate and does not net later sells, taxes, or fees.

Cynthia Axne & CVET trading FAQ

Is it legal for Cynthia Axne to trade Covetrus, Inc. (CVET) [ST] F ILINg S TATuS : New S ubHOLdINg O F : Cindy Axne IRA (CVET) stock?

Yes. Members of Congress are allowed to trade individual stocks, including Covetrus, Inc. (CVET) [ST] F ILINg S TATuS : New S ubHOLdINg O F : Cindy Axne IRA (CVET), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.

When did Cynthia Axne buy CVET?

Cynthia Axne disclosed a purchase of $1,001 - $15,000 of Covetrus, Inc. (CVET) [ST] F ILINg S TATuS : New S ubHOLdINg O F : Cindy Axne IRA (CVET) on February 6, 2019, according to public STOCK Act filings.

How has CVET performed since Cynthia Axne's trade?

Since Cynthia Axne bought CVET on February 6, 2019, the stock is up +0.00%, versus +198.21% for the S&P 500 over the same period, an outperformance of -198.21%.

How many times has Cynthia Axne traded CVET?

Cynthia Axne has disclosed 3 CVET trades since 2019. Every disclosed trade is listed on this page.

How soon must members of Congress disclose a trade?

Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.

Where can I see all congressional CVET trades?

Quantellect tracks every disclosed congressional trade in Covetrus, Inc. (CVET) [ST] F ILINg S TATuS : New S ubHOLdINg O F : Cindy Axne IRA (CVET) on the Covetrus, Inc. (CVET) [ST] F ILINg S TATuS : New S ubHOLdINg O F : Cindy Axne IRA congressional trading page, which aggregates filings across all members of Congress.

Cynthia Axne's CVET tradesAll congressional filings for Covetrus, Inc. (CVET) [ST] F ILINg S TATuS : New S ubHOLdINg O F : Cindy Axne IRACynthia Axne's full profile

Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.